In collaboration with DNAstack and Verily, Target ALS has launched a first-of-its-kind Data Engine that will provide no-strings-attached access to comprehensive datasets and analysis tools to fuel the discovery of treatments and biomarkers for ALS.
Through the portal, researchers worldwide can access well-characterized data collections from Target ALS’ Scientific Core Facilities, including postmortem tissue, longitudinal biofluids, and stem cells. Data can be mined for multi-omic analysis to identify novel pathological and genetic biomarkers of both sporadic and genetic forms of ALS and their progression.
New data will be uploaded every 4-6 months. Currently, the Postmortem Tissue Collection is available and contains unique datasets generated using state-of-the art methodologies including whole genome sequencing, spatial and bulk transcriptomics, semi-quantitative histopathology, digitized images of pTDP43 staining, and clinical and demographic data from 260 ALS cases, Frontotemporal Dementia (FTD) cases, and non-neurological controls.
The Natural History Study and Stem Cell Collections are now also available.
